The latest FDA commissioner may be in an uncomfortable place where the Trump administration's budget proposal is concerned, but Scott Gottlieb told a congressional committee that the agency will undertake several actions to bolster competition in the drug marketplace, including the publication of a list of off-patent drugs that are not represented by a generic.